INT158070

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 23
Total Number 23
Disease Relevance 19.93
Pain Relevance 10.90

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Aes)
Anatomy Link Frequency
liver 2
Aes (Rattus norvegicus)
Pain Link Frequency Relevance Heat
headache 38 100.00 Very High Very High Very High
abdominal pain 28 100.00 Very High Very High Very High
Central nervous system 16 100.00 Very High Very High Very High
Ziconotide 1200 99.98 Very High Very High Very High
Infliximab 372 98.80 Very High Very High Very High
depression 37 98.56 Very High Very High Very High
Morphine 384 97.60 Very High Very High Very High
withdrawal 36 96.00 Very High Very High Very High
backache 7 95.28 Very High Very High Very High
Pain 330 94.48 High High
Disease Link Frequency Relevance Heat
Cognitive Disorder 120 100.00 Very High Very High Very High
Vomiting 103 100.00 Very High Very High Very High
Confusion 90 100.00 Very High Very High Very High
Headache 41 100.00 Very High Very High Very High
Abdominal Pain 28 100.00 Very High Very High Very High
Constipation 20 100.00 Very High Very High Very High
Pressure Volume 2 Under Development 18 100.00 Very High Very High Very High
Hypertension 11 100.00 Very High Very High Very High
Flatulence 3 100.00 Very High Very High Very High
Pigment Disorder 2 100.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Serious AEs were reported by 61 patients (15.1 percent), but only five were considered related to study drug.
Localization (reported) of AEs
1) Confidence 0.65 Published 2010 Journal J Opioid Manag Section Body Doc Link 21046929 Disease Relevance 0.06 Pain Relevance 0
The most frequently reported AEs (?
Localization (reported) of AEs
2) Confidence 0.38 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2908075 Disease Relevance 1.05 Pain Relevance 0.37
The most commonly reported AEs (?
Localization (reported) of AEs
3) Confidence 0.33 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 0.93 Pain Relevance 1.16
The relatively slow onset of AEs suggests that increments in the dosing of ziconotide be made no more frequently than weekly.33
Localization (onset) of AEs associated with ziconotide
4) Confidence 0.33 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 0.08 Pain Relevance 1.00
The neurocognitive AEs, such as confusion, disorientation, memory impairment, speech difficulties, impaired concentration, mental slowing, or thought abnormalities, are the most troublesome of the ziconotide-related CNS AEs and, if not manageable by dose reduction, often required drug discontinuation.38
Localization (related) of AEs associated with cognitive disorder, congenital anomalies, ziconotide, central nervous system and confusion
5) Confidence 0.33 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 1.98 Pain Relevance 0.73
The neurocognitive AEs, such as confusion, disorientation, memory impairment, speech difficulties, impaired concentration, mental slowing, or thought abnormalities, are the most troublesome of the ziconotide-related CNS AEs and, if not manageable by dose reduction, often required drug discontinuation.38
Localization (slowing) of AEs associated with cognitive disorder, congenital anomalies, ziconotide, central nervous system and confusion
6) Confidence 0.33 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 2.19 Pain Relevance 0.80
The neurocognitive AEs, such as confusion, disorientation, memory impairment, speech difficulties, impaired concentration, mental slowing, or thought abnormalities, are the most troublesome of the ziconotide-related CNS AEs and, if not manageable by dose reduction, often required drug discontinuation.38
Localization (required) of AEs associated with cognitive disorder, congenital anomalies, ziconotide, central nervous system and confusion
7) Confidence 0.33 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 1.97 Pain Relevance 0.74
The most frequently reported AEs were reduction in appetite (28.0%), weight loss (10.0%), and increased phenytoin levels in patients concurrently taking phenytoin (10.0%).
Localization (reported) of AEs associated with weight loss
8) Confidence 0.33 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 1.09 Pain Relevance 0.04
No serious AEs or discontinuations as a result of AEs were reported during the study.
Localization (reported) of AEs
9) Confidence 0.29 Published 2009 Journal Drugs Aging Section Body Doc Link 19220066 Disease Relevance 0 Pain Relevance 0
Along with diarrhea, headache was also one of the most frequently reported AEs in these trials.
Localization (reported) of AEs associated with diarrhoea and headache
10) Confidence 0.21 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936292 Disease Relevance 1.00 Pain Relevance 0.32
Behavior-related problems were among the most commonly reported AEs in 7 of 12 trials.
Localization (reported) of AEs
11) Confidence 0.20 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2655081 Disease Relevance 0.42 Pain Relevance 0.24
For the infliximab vs placebo groups during the same period, the frequency of AEs (84.8 vs 83.6%), related AEs (44.8 vs 41.8%) and SAEs (11.5 vs 11.8%) were similar; however, a higher proportion of patients in the infliximab group compared with the placebo group reported related SAEs (4.8 vs 2.7%), discontinued due to AEs (4.8 vs 0.9%), and discontinued due to SAEs (2.4 vs 0%).
Localization (related) of AEs associated with infliximab
12) Confidence 0.13 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 0.48 Pain Relevance 0.75
All patients who received at least one dose of study drug were evaluated for safety, including all reported AEs, serious AEs (SAEs), and clinically significant changes in vital signs, physical exams, and clinical laboratory test abnormalities.
Localization (serious) of AEs associated with congenital anomalies
13) Confidence 0.13 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 0.38 Pain Relevance 0.35
All patients who received at least one dose of study drug were evaluated for safety, including all reported AEs, serious AEs (SAEs), and clinically significant changes in vital signs, physical exams, and clinical laboratory test abnormalities.
Localization (serious) of AEs associated with congenital anomalies
14) Confidence 0.13 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 0.38 Pain Relevance 0.35
For the infliximab vs placebo groups during the same period, the frequency of AEs (84.8 vs 83.6%), related AEs (44.8 vs 41.8%) and SAEs (11.5 vs 11.8%) were similar; however, a higher proportion of patients in the infliximab group compared with the placebo group reported related SAEs (4.8 vs 2.7%), discontinued due to AEs (4.8 vs 0.9%), and discontinued due to SAEs (2.4 vs 0%).
Localization (related) of AEs associated with infliximab
15) Confidence 0.13 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 0.48 Pain Relevance 0.74
The most frequently reported AEs (by preferred term) during this study are listed in Table 3.
Localization (reported) of AEs
16) Confidence 0.11 Published 2008 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2542997 Disease Relevance 0.47 Pain Relevance 0.06
AEs that were considered by the investigators to be possibly related to the study medication were reported in 13 out of 163 (8.0%) patients, these were nausea, abdominal pain, constipation, eructation, white blood cell count increase, headache, night sweats, pigmentation disorder, hypertension and hypotension; other AEs related to laboratory parameters and included two reports of increased alanine aminotransferase levels and one each of aspartate aminotransferase increase, liver function test abnormality and CRP increase.
Localization (reported) of AEs in liver associated with hot flashes, flatulence, abdominal pain, pigment disorder, constipation, vomiting, pressure volume 2 under development, hypertension and headache
17) Confidence 0.07 Published 2010 Journal Nephrology Dialysis Transplantation Section Body Doc Link PMC2905444 Disease Relevance 1.25 Pain Relevance 0.25
AEs that were considered by the investigators to be possibly related to the study medication were reported in 13 out of 163 (8.0%) patients, these were nausea, abdominal pain, constipation, eructation, white blood cell count increase, headache, night sweats, pigmentation disorder, hypertension and hypotension; other AEs related to laboratory parameters and included two reports of increased alanine aminotransferase levels and one each of aspartate aminotransferase increase, liver function test abnormality and CRP increase.
Localization (reported) of AEs in liver associated with hot flashes, flatulence, abdominal pain, pigment disorder, constipation, vomiting, pressure volume 2 under development, hypertension and headache
18) Confidence 0.07 Published 2010 Journal Nephrology Dialysis Transplantation Section Body Doc Link PMC2905444 Disease Relevance 1.53 Pain Relevance 0.28
In the Streim et al (2004) study, AEs that occurred at the rate of ?
Localization (occurred) of AEs
19) Confidence 0.06 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682381 Disease Relevance 1.50 Pain Relevance 0
Tolerability was assessed by spontaneous reporting of AEs.
Localization (reporting) of AEs
20) Confidence 0.06 Published 2007 Journal BMC Clin Pharmacol Section Body Doc Link PMC2194660 Disease Relevance 0.07 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox